Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Diabetes

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 68 articles: HTML format

Single Articles

October 2025
1. ROSENSTOCK J, Carr MC, Child CJ
   Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes. Reply.
   N Engl J Med. 2025;393:1443-1444.
   PubMed    
   
   
   
2. SAMAJDAR SS, Joshi SR, Mukherjee S
   Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes.
   N Engl J Med. 2025;393:1442-1443.
   PubMed    
   
   
   
3. KHAN H, Adnan F
   Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes.
   N Engl J Med. 2025;393:1442.
   PubMed    
   
   
   September 2025
4. HEROLD KC, Pober JS
   Replacement of Beta Cells for Type 1 Diabetes.
   N Engl J Med. 2025;393:917-921.
   PubMed    
   
   
   
5. CARLSSON PO, Hu X, Scholz H, Ingvast S, et al
   Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression.
   N Engl J Med. 2025;393:887-894.
   PubMed     Abstract available
   
   
   August 2025
6. HALES CM
   Expanding the Treat-to-Target Toolbox for Obesity and Diabetes Care.
   N Engl J Med. 2025;393:712-714.
   PubMed    
   
   
   
7. KUDVA YC, Beck RW
   A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. Reply.
   N Engl J Med. 2025;393:618-619.
   PubMed    
   
   
   
8. ZHANG F, Zhong Y
   A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.
   N Engl J Med. 2025;393:618.
   PubMed    
   
   
   
9. SAXON D
   A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.
   N Engl J Med. 2025;393:617-618.
   PubMed    
   
   
   
10. ZOCCALI C, Mallamaci F
    Combination Therapy for Chronic Kidney Disease and Type 2 Diabetes - A Promising Prelude.
    N Engl J Med. 2025;393:601-602.
    PubMed    
    
    
    July 2025
11. BI Y, Xu Y, Wang W
    Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. Reply.
    N Engl J Med. 2025;393:97-98.
    PubMed    
    
    
    
12. GROSSMAN E, Messerli FH
    Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.
    N Engl J Med. 2025;393:97.
    PubMed    
    
    
    
13. FERNANDEZ-FERNANDEZ B, Sarafidis P, Ortiz A
    Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.
    N Engl J Med. 2025;393:96-97.
    PubMed    
    
    
    
14. JOLOBE OMP
    Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.
    N Engl J Med. 2025;393:96.
    PubMed    
    
    
    
15. SCHMIEDER RE
    Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.
    N Engl J Med. 2025;393:95-96.
    PubMed    
    
    
    June 2025
16. JASTREBOFF AM, Bunck MC, Ahmad NN
    Tirzepatide for Obesity Treatment and Diabetes Prevention. Reply.
    N Engl J Med. 2025;392:2492-2493.
    PubMed    
    
    
    
17. SHUKLA AK, Bhavya B
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2025;392:2492.
    PubMed    
    
    
    
18. BIRKENFELD AL, Bergman M, Stefan N
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2025;392:2491-2492.
    PubMed    
    
    
    
19. JASTREBOFF AM, Ryan DH, Bays HE, Ebeling PR, et al
    Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.
    N Engl J Med. 2025 Jun 23. doi: 10.1056/NEJMoa2504214.
    PubMed     Abstract available
    
    
    
20. ROSENSTOCK J, Bailey T, Connery L, Miller E, et al
    Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy.
    N Engl J Med. 2025 Jun 22. doi: 10.1056/NEJMoa2502796.
    PubMed     Abstract available
    
    
    
21. INGELFINGER JR, Rosen CJ
    Weekly Insulins and Therapeutic Burden in Type 2 Diabetes.
    N Engl J Med. 2025 Jun 22. doi: 10.1056/NEJMe2508147.
    PubMed    
    
    
    
22. DAVIES MJ, Bajaj HS, Broholm C, Eliasen A, et al
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
    N Engl J Med. 2025 Jun 22. doi: 10.1056/NEJMoa2502082.
    PubMed     Abstract available
    
    
    
23. ROSENSTOCK J, Hsia S, Nevarez Ruiz L, Eyde S, et al
    Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
    N Engl J Med. 2025 Jun 21. doi: 10.1056/NEJMoa2505669.
    PubMed     Abstract available
    
    
    
24. REICHMAN TW, Markmann JF, Odorico J, Witkowski P, et al
    Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes.
    N Engl J Med. 2025 Jun 20. doi: 10.1056/NEJMoa2506549.
    PubMed     Abstract available
    
    
    
25. AGARWAL R, Green JB, Heerspink HJL, Mann JFE, et al
    Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
    N Engl J Med. 2025 Jun 5. doi: 10.1056/NEJMoa2410659.
    PubMed     Abstract available
    
    
    
26. CHEUNG A, Quintos JBQ, Agarwal S
    Setting for Initial Education about Type 1 Diabetes.
    N Engl J Med. 2025;392:2164-2167.
    PubMed    
    
    
    May 2025
27. HATIPOGLU B
    Automated Insulin Pump in Type 2 Diabetes.
    N Engl J Med. 2025;392:1862-1863.
    PubMed    
    
    
    March 2025
28. MAGNUSSEN C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, et al
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025 Mar 30. doi: 10.1056/NEJMoa2415879.
    PubMed     Abstract available
    
    
    
29. MCGUIRE DK, Marx N, Mulvagh SL, Deanfield JE, et al
    Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
    N Engl J Med. 2025 Mar 29. doi: 10.1056/NEJMoa2501006.
    PubMed     Abstract available
    
    
    
30. ANAND S, Beddhu S
    BPROAD - End of the Road for Debate on Systolic Blood-Pressure Goals in Type 2 Diabetes?
    N Engl J Med. 2025;392:1230-1232.
    PubMed    
    
    
    
31. KUDVA YC, Raghinaru D, Lum JW, Graham TE, et al
    A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.
    N Engl J Med. 2025 Mar 19. doi: 10.1056/NEJMoa2415948.
    PubMed     Abstract available
    
    
    February 2025
32. LI S, Mikhael B, van Zyl DG
    Choice of Intravenous Fluid for Resuscitation in Diabetic Ketoacidosis.
    N Engl J Med. 2025;392:923-926.
    PubMed    
    
    
    November 2024
33. BI Y, Li M, Liu Y, Li T, et al
    Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.
    N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2412006.
    PubMed     Abstract available
    
    
    
34. RUBIN EJ, Leopold J, Morrissey S
    NEJM at AHA - Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.
    N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMe2414476.
    PubMed    
    
    
    
35. JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
    PubMed     Abstract available
    
    
    
36. PERKOVIC V, Tuttle KR, Pratley R
    Semaglutide for Chronic Kidney Disease in Type 2 Diabetes. Reply.
    N Engl J Med. 2024;391:1757.
    PubMed    
    
    
    
37. DA HORA PASSOS R, Narciso RC, da Silva AA
    Semaglutide for Chronic Kidney Disease in Type 2 Diabetes.
    N Engl J Med. 2024;391:1757.
    PubMed    
    
    
    October 2024
38. ISRAEL A, Vinker S, Merzon E
    More on Type 2 Diabetes in Patients with G6PD Deficiency. Reply.
    N Engl J Med. 2024;391:1664.
    PubMed    
    
    
    
39. CUI W
    More on Type 2 Diabetes in Patients with G6PD Deficiency.
    N Engl J Med. 2024;391:1664.
    PubMed    
    
    
    
40. HERRINGTON WG, Staplin N, Agrawal N, Wanner C, et al
    Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
    N Engl J Med. 2024 Oct 25. doi: 10.1056/NEJMoa2409183.
    PubMed     Abstract available
    
    
    September 2024
41. WYSHAM C, Bajaj HS, Del Prato S, Franco DR, et al
    Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.
    N Engl J Med. 2024 Sep 10. doi: 10.1056/NEJMoa2403953.
    PubMed     Abstract available
    
    
    August 2024
42. PERSAD G, Dellgren JL, Emanuel EJ
    Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists. Reply.
    N Engl J Med. 2024;391:776.
    PubMed    
    
    
    
43. GONG JY, Shaw JE
    Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    N Engl J Med. 2024;391:775-776.
    PubMed    
    
    
    
44. MENSAH MO, Freitas DJ, Cartwright JR
    Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    N Engl J Med. 2024;391:775.
    PubMed    
    
    
    
45. MAKARY N, Razali Q
    Diabetes-Associated Scleredema.
    N Engl J Med. 2024;391:e15.
    PubMed    
    
    
    
46. ISRAEL A, Raz I, Vinker S, Magen E, et al
    Type 2 Diabetes in Patients with G6PD Deficiency.
    N Engl J Med. 2024;391:568-569.
    PubMed    
    
    
    July 2024
47. KOSIBOROD MN, Petrie MC, Borlaug BA
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes. Reply.
    N Engl J Med. 2024;391:381-382.
    PubMed    
    
    
    
48. AMMON JP, Jackson CD
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:381.
    PubMed    
    
    
    
49. WAGNER J
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:380-381.
    PubMed    
    
    
    
50. COHEN C, Cohen R, Sabouret P
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:380.
    PubMed    
    
    
    
51. HERRINGTON WG, Haynes R
    Diabetic Kidney Disease - Semaglutide Flows into the Mainstream.
    N Engl J Med. 2024;391:178-179.
    PubMed    
    
    
    June 2024
52. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:2227.
    PubMed    
    
    
    
53. MAAHS DM, Svensson J
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226-2227.
    PubMed    
    
    
    
54. WENSTEDT EFE, Vogt L
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226.
    PubMed    
    
    
    
55. CEFALU WT, Arreaza-Rubin G
    Engineering an Insulin Complex to Treat Diabetes.
    N Engl J Med. 2024;390:2214-2216.
    PubMed    
    
    
    
56. ROY N, Mandal M
    Insulin-Induced Lipohypertrophy.
    N Engl J Med. 2024;390:e60.
    PubMed    
    
    
    May 2024
57. BICHET DG, Bockenhauer D
    Thirst, Hunger, and Nephrogenic Diabetes Insipidus.
    N Engl J Med. 2024;390:1922-1924.
    PubMed    
    
    
    
58. EMANUEL EJ, Dellgren JL, McCoy MS, Persad G, et al
    Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    N Engl J Med. 2024;390:1839-1842.
    PubMed    
    
    
    
59. PERKOVIC V, Tuttle KR, Rossing P, Mahaffey KW, et al
    Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
    N Engl J Med. 2024 May 24. doi: 10.1056/NEJMoa2403347.
    PubMed     Abstract available
    
    
    April 2024
60. KOSIBOROD MN, Petrie MC, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2313917.
    PubMed     Abstract available
    
    
    
61. BUTLER J, Jones WS, Udell JA, Anker SD, et al
    Empagliflozin after Acute Myocardial Infarction.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2314051.
    PubMed     Abstract available
    
    
    
62. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:1207-1217.
    PubMed    
    
    
    
63. VAZQUEZ MA, Oliver G, Amarasingham R, Sundaram V, et al
    Pragmatic Trial of Hospitalization Rate in Chronic Kidney Disease.
    N Engl J Med. 2024;390:1196-1206.
    PubMed     Abstract available
    
    
    
64. FOURMAN LT, Tsai LL, Brown RJ, O'Rahilly S, et al
    Case 10-2024: A 46-Year-Old Woman with Hyperglycemia Refractory to Insulin Therapy.
    N Engl J Med. 2024;390:1219-1229.
    PubMed    
    
    
    March 2024
65. HUGHES MS, Addala A, Buckingham B
    Digital Technology for Diabetes. Reply.
    N Engl J Med. 2024;390:963-964.
    PubMed    
    
    
    
66. BERG TJ
    Digital Technology for Diabetes.
    N Engl J Med. 2024;390:963.
    PubMed    
    
    
    
67. TUMMINIA A, Gullo D, Frasca F
    Digital Technology for Diabetes.
    N Engl J Med. 2024;390:962-963.
    PubMed    
    
    
    
68. KINNY-KOSTER B, Michalski CW, Loos M
    Digital Technology for Diabetes.
    N Engl J Med. 2024;390:962.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.